| Autor: |
Jain N; Takeda Development Center Americas, Inc., Cambridge, MA, USA., Oldenburg J; Institute for Experimental Hematology and Transfusion Medicine, Bonn University Clinic, Bonn, Germany., Ozelo MC; Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, São Paulo, Brazil., Sun SX; Takeda Development Center Americas, Inc., Cambridge, MA, USA., Tang L; Takeda Pharmaceuticals International AG, Zürich, Switzerland., Tzivelekis S; Takeda Development Center Americas, Inc., Cambridge, MA, USA. |
| Abstrakt: |
Hemophilia, von Willebrand disease (VWD), and thrombotic thrombocytopenic purpura (TTP) are rare diseases affecting normal hemostasis. Although they differ in their pathogenesis and clinical manifestation, if left undiagnosed and untreated, all these conditions can result in severe long-term consequences and can be potentially life-threatening. This article summarizes a poster series funded by Takeda and presented virtually at the 29th annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in 2021: Data from real-world evidence highlight the importance of joint health and personalized prophylaxis to prevent bleeding for patients with hemophilia, the need to further raise disease awareness in support of timely diagnosis and access to treatment in general practice settings for patients with VWD, and describe the clinical burden for patients with TTP and the importance to advance treatment options for these patients. |
